177 related articles for article (PubMed ID: 35096623)
1. Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review.
Barozzi E; Bucelli C; Grifoni FI; Gianelli U; Iurlo A; Cattaneo D
Front Oncol; 2021; 11():819097. PubMed ID: 35096623
[TBL] [Abstract][Full Text] [Related]
2. Systemic mastocytosis with myeloid sarcoma and B-CLL: molecular and clonal heterogeneity in a rare case of SM-AHN with review of literature.
Decruyenaere P; Mazure D; Moors I; Van Dorpe J; Van der Linden M; Denys B; Hofmans M; Offner F
Acta Clin Belg; 2023 Feb; 78(1):58-66. PubMed ID: 35098906
[TBL] [Abstract][Full Text] [Related]
3. An adult patient with systemic mastocytosis and B-acute lymphoblastic leukemia.
Iliakis T; Rougkala N; Diamantopoulos PT; Papadopoulou V; Kalala F; Zervakis K; Giannakopoulou N; Chatzinikolaou P; Levidou G; Lakiotaki E; Korkolopoulou P; Patsouris E; Variami E; Viniou NA
Case Rep Med; 2014; 2014():526129. PubMed ID: 25431599
[TBL] [Abstract][Full Text] [Related]
4. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.
Wang SA; Hutchinson L; Tang G; Chen SS; Miron PM; Huh YO; Jones DM; Bueso-Ramos C; Verstovsek S; Medeiros LJ; Miranda RN
Am J Hematol; 2013 Mar; 88(3):219-24. PubMed ID: 23440662
[TBL] [Abstract][Full Text] [Related]
5. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract][Full Text] [Related]
6. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Evolution of
Sciumè M; Ceparano G; Eller-Vainicher C; Fabris S; Lonati S; Croci GA; Baldini L; Grifoni FI
Front Oncol; 2021; 11():734025. PubMed ID: 34917498
[TBL] [Abstract][Full Text] [Related]
8. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
9. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
10. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2011 Apr; 86(4):362-71. PubMed ID: 21442641
[TBL] [Abstract][Full Text] [Related]
11. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
[TBL] [Abstract][Full Text] [Related]
12. Mast Cell Sarcoma of the Retroperitoneum With Concurrent Systemic Mastocytosis and an Undisclosed Associated Hematologic Neoplasm: A Case Report.
Chen I; Liao JB; Lin JC; Hsieh PP; Hsieh MY
Clin Pathol; 2022; 15():2632010X221123539. PubMed ID: 36119438
[TBL] [Abstract][Full Text] [Related]
13. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies.
Pardanani A; Lim KH; Lasho TL; Finke C; McClure RF; Li CY; Tefferi A
Blood; 2009 Oct; 114(18):3769-72. PubMed ID: 19713463
[TBL] [Abstract][Full Text] [Related]
14. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
[TBL] [Abstract][Full Text] [Related]
15. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
16. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
Horny HP; Sotlar K; Sperr WR; Valent P
J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
[TBL] [Abstract][Full Text] [Related]
17. Systemic Mastocytosis: Advances in Diagnosis and Current Management.
Pullarkat ST; Wu W; Pullarkat V
Cancer Treat Res; 2021; 181():167-178. PubMed ID: 34626361
[TBL] [Abstract][Full Text] [Related]
18. [Mastocytosis and eosinophilic leukemia: diagnostics and classification].
Sotlar K; Valent P; Horny HP
Pathologe; 2012 Nov; 33(6):539-52. PubMed ID: 23085697
[TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2016 Nov; 91(11):1146-1159. PubMed ID: 27762455
[TBL] [Abstract][Full Text] [Related]
20. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases.
Damaj G; Joris M; Chandesris O; Hanssens K; Soucie E; Canioni D; Kolb B; Durieu I; Gyan E; Livideanu C; Chèze S; Diouf M; Garidi R; Georgin-Lavialle S; Asnafi V; Lhermitte L; Lavigne C; Launay D; Arock M; Lortholary O; Dubreuil P; Hermine O
PLoS One; 2014; 9(1):e85362. PubMed ID: 24465546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
